These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21305642)

  • 1. Prognostic value of SOX2 expression in neuroblastoma.
    Gómez-Mateo Mdel C; Piqueras M; Påhlman S; Noguera R; Navarro S
    Genes Chromosomes Cancer; 2011 May; 50(5):374-7. PubMed ID: 21305642
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma.
    Gebauer S; Yu AL; Omura-Minamisawa M; Batova A; Diccianni MB
    Genes Chromosomes Cancer; 2004 Dec; 41(4):297-308. PubMed ID: 15390183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic role of urinary catecholamines in infants with disseminated neuroblastoma may be mediated by MYCN amplification.
    Parodi S; Papio F; Haupt R; Conte M; De Bernardi B
    Pediatr Blood Cancer; 2007 May; 48(5):593; author reply 593-4. PubMed ID: 16937359
    [No Abstract]   [Full Text] [Related]  

  • 4. "Let's try it one more, once".
    Woods WG
    Pediatr Blood Cancer; 2006 Mar; 46(3):271-2. PubMed ID: 16078229
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuroblastoma--from genetic profiles to clinical challenge.
    Kushner BH; Cheung NK
    N Engl J Med; 2005 Nov; 353(21):2215-7. PubMed ID: 16306518
    [No Abstract]   [Full Text] [Related]  

  • 6. The MYCN enigma: significance of MYCN expression in neuroblastoma.
    Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
    Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.
    Liu PY; Erriquez D; Marshall GM; Tee AE; Polly P; Wong M; Liu B; Bell JL; Zhang XD; Milazzo G; Cheung BB; Fox A; Swarbrick A; Hüttelmaier S; Kavallaris M; Perini G; Mattick JS; Dinger ME; Liu T
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma.
    Combaret V; Bergeron C; Noguera R; Iacono I; Puisieux A
    J Clin Oncol; 2005 Dec; 23(34):8919-20; author reply 8920. PubMed ID: 16314658
    [No Abstract]   [Full Text] [Related]  

  • 9. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-directed therapy and research in neuroblastoma.
    Liu YL; Miser JS; Hsu WM
    J Formos Med Assoc; 2014 Dec; 113(12):887-9. PubMed ID: 25499951
    [No Abstract]   [Full Text] [Related]  

  • 12. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
    Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
    Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locoregional MYCN-amplified neuroblastoma.
    Morales La Madrid A; Volchenboum S; Gastier-Foster JM; Pyatt R; Liu D; Pytel P; Lavarino C; Rodriguez E; Cohn SL
    Pediatr Blood Cancer; 2012 Oct; 59(4):736-8. PubMed ID: 22213566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization.
    Stock C; Bozsaky E; Watzinger F; Poetschger U; Orel L; Lion T; Kowalska A; Ambros PF
    Am J Pathol; 2008 Jan; 172(1):203-14. PubMed ID: 18165268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathology of peripheral neuroblastic tumors].
    Wang L; He LJ; Shimada H
    Zhonghua Bing Li Xue Za Zhi; 2012 Apr; 41(4):283-8. PubMed ID: 22800533
    [No Abstract]   [Full Text] [Related]  

  • 17. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.
    Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF
    Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
    Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
    Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addiction to B-MYB.
    Gustafson WC; Weiss WA
    Oncotarget; 2010 Aug; 1(4):235-236. PubMed ID: 21304174
    [No Abstract]   [Full Text] [Related]  

  • 20. How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers.
    Maris JM
    Pediatr Blood Cancer; 2005 Dec; 45(7):869-70. PubMed ID: 16206200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.